Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI®

A Phase I interventional Clinical Trial was performed with a potential tuberculosis vaccine, based oil deroxified cellular fragments of M tuberculosis, named RUTI (R). The objective was to evaluate the safety profile and T-cell immune responses over a 6-month period following subcutaneous inoculation. The double-blind. randomized and placebo-control led trial was conducted in healthy Volunteers, all recruited at one site. RUTI (R), at each of the four tested doses, starting from 5 mu g and going Lip to 200 jag. and placebo were inoculated to groups of 4 and 2 volunteers respectively, consecutively. RUTI (R) appeared to be well tolerated as judged by local and systemic clinical evaluation, though vaccine dose dependent local adverse reactions were recorded T-cell responses of blood lymphocytes to PPD and a number of antigen subunits were elevated, when compared with controls Subjects These results support the feasibility Of future evaluation, to be targeted at subjects with latent tuberculosis infection (LTBI). (C) 2009 Elsevier Ltd All rights reserved